Boji Medical Technology(300404.SZ): "TBA tablets" drug clinical trials approved.
Boji Pharmaceuticals (300404.SZ) announced that the company is cooperating with Guangdong Gumaide Health Technology Co., Ltd. to jointly develop...
Boji Medical Technology (300404.SZ) announcement: The company has collaborated with Guangdong Gumaide Health Technology Co., Ltd. to develop and jointly apply for approval for the "TBA tablets," which has been approved by the National Medical Products Administration, with the issuance of the "Drug Clinical Trial Approval Notice." TBA is a new, structurally defined compound with pharmacological effects and clinical value. It is a class 1 innovative drug that has not been launched domestically or internationally, and its proposed indication is drug-resistant pulmonary tuberculosis.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
